Scholar Rock Holding Corporation is a biopharmaceutical company. Co. is focused on the discovery, development and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled the Co. to develop a proprietary platform for the development of monoclonal antibodies that locally and selectively target the precursor. The SRRK average annual return since 2018 is shown above.
The Average Annual Return on the SRRK average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SRRK average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SRRK average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free SRRK Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
